| Literature DB >> 16086682 |
Giuseppina Tesco1, Andrea Ginestroni, Mikko Hiltunen, Minji Kim, Georgia Dolios, Bradley T Hyman, Rong Wang, Oksana Berezovska, Rudolph E Tanzi.
Abstract
The 37-43 amino acid Abeta peptide is the principal component of beta-amyloid deposits in Alzheimer's disease (AD) brain, and is derived by serial proteolysis of the amyloid precursor protein (APP) by beta- and gamma-secretase. gamma-Secretase also cleaves APP at Val50 in the Abeta numbering (epsilon cleavage), resulting in the release of a fragment called APP intracellular domain (AICD). The aim of this study was to determine whether amino acid substitutions in the APP transmembrane domain differentially affect Abeta and AICD generation. We found that the APPV715F substitution, which has been previously shown to dramatically decrease Abeta40 and Abeta42 while increasing Abeta38 levels, does not affect in vitro generation of AICD. Furthermore, we found that the APPL720P substitution, which has been previously shown to prevent in vitro generation of AICD, completely prevents Abeta generation. Using a fluorescence resonance energy transfer (FRET) method, we next found that both the APPV715F and APPL720P substitutions significantly increase the distance between the N- and C-terminus of presenilin 1 (PS1), which has been proposed to contain the catalytic site of gamma-secretase. In conclusion, both APPV715F and APPL720P change PS1 conformation with differential effects on Abeta and AICD production.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16086682 DOI: 10.1111/j.1471-4159.2005.03381.x
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372